The immediate future for the medical treatment of atrial fibrillation

Bibliography

• KANNEL WB, WOLF PA, BENJAMIN EJ, LEVY D: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. (1998) 82(8A):2N–9N.
   Google Scholar
• FUSTER V, RYDEN LE, ASINGER RW et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur: Heart J. (2001) 22(20):1852–1923.
   PubMed Web of Science ®Google Scholar
• BASZKO A, RINALDI CA, SIMON RD, GILL JS: Atrial fibrillation current and future treatments: radiofrequency ablation and novel pacing techniques. hat. J. Clin. Piaci (2002) 56(5):370–376.
   PubMed Web of Science ®Google Scholar
• COX JL, BOINEAU JP, SCHUESSLER RB, JAQUISS RD, LAPPAS DG: Modification of the maze procedure for atrial flutter and atrial fibrillation. I. Rationale and surgical results. Thorac. Cardiovasc. Surg. 1995 110(2):473–484.
   Web of Science ®Google Scholar
• JAIS P, HAISSAGUERRE M, SHAH DC et al.: A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation (1997) 95(3):572–576.
   Google Scholar
• WIJFFELS MCEF, KIRCHHOF CJHJ, DORLAND R, ALLESSIE MA: Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation (1995) 92(7):1954–1968.
   PubMed Web of Science ®Google Scholar
• THIJSSEN VL, VAN DER VELDEN HM, VAN ANKEREN EP et al.: Analysis of altered gene expression during sustained atrial fibrillation in the goat. Cardiovasc. Res. (2002) 54(2):427–437.
   PubMed Web of Science ®Google Scholar
• LID, SHINAGAWA K, PANG L et al: Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation (2001) 104(21):2608–2614.
   Google Scholar
• PEDERSEN OD, BAGGER H, KOBER L, TORP-PEDERSEN C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation (1999) 100(4):376–380.
   PubMed Web of Science ®Google Scholar
• VAUGHAN WILLIAMS EM: A classification of antiarrhythmic actions reassessed after a decade of new drugs. Clin.Pharmacol. (1984) 24(4):129–147.
   Google Scholar
• THE CARDIAC ARRHYTHMIA SUPPRESSION TRIAL II INVESTIGATORS: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl. I Med. (1992) 327(4):227–233.
   PubMed Web of Science ®Google Scholar
• TASK FORCE OF THE WORKING GROUP ON ARRHYTHMIAS OF THE EUROPEAN SOCIETY OF CARDIOLOGY. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation (1991) 84(4):1831–1851.
   PubMed Web of Science ®Google Scholar
• ACKERMAN MJ: The long QT syndrome: ion channel diseases of the heart. Mayo Clin. Proc. (1998) 73(3):250–269.
   PubMed Web of Science ®Google Scholar
• PRIORI SG, BARHANIN J, HAUER RN et al.: Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur. Heart (1999) 20(3):174–195.
   PubMed Web of Science ®Google Scholar
• HOHNLOSER SH, SINGH BN: Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. Cardiovasc. Electrophysiol (1995) 6(2):920–936.
   PubMedGoogle Scholar
• JULIAN DG, CAMM AJ, FRANGIN G et al.: Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet (1997) 349(9053):667–674.
   PubMed Web of Science ®Google Scholar
• CAIRNS JA, CONNOLLY SJ, ROBERTS R, GENT M: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet (1997) 349(9053):675–682.
   PubMed Web of Science ®Google Scholar
• DOVAL HC, NUL DR, PERRONE SV, BORTMAN GR, CURIEL R, (GESICA) fGdEd1SelIeA: randomized trial of low dose amiodarone in severe congestive heart failure. Lancet (1994) 344:493–498.
   PubMed Web of Science ®Google Scholar
• SINGH SN, FLETCHER RD, FISHER SG et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N. Engl.' Med. (1995) 333:77–82.
   PubMed Web of Science ®Google Scholar
• JULIAN DG, PRESCOTT RJ, JACKSON FS, SZEKELY P: Controlled trial of sotalol for one year after myocardial infarction. Lancet (1982) 1(8282):1142–1147.
   PubMed Web of Science ®Google Scholar
• KOBER L, BLOCH-THOMSEN PE, MOLLER M et al.: Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet (2000) 356(9247):2052–2058.
   PubMed Web of Science ®Google Scholar
• TORP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN PE et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl. I Med. (1999) 341(12):857–865.
   PubMed Web of Science ®Google Scholar
• BRENDORP B, ELMING H, JUN L et al.:QTc Interval as a Guide to Select Those Patients With Congestive Heart Failure and Reduced Left Ventricular Systolic Function Who Will Benefit From Antiarrhythmic Treatment With Dofetilide. Circulation (2001) 103(10):1422–1427.
   PubMed Web of Science ®Google Scholar
• WALDO AL, CAMM AJ, DERUYTER H et al: Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet (1996) 348:7–12.
   PubMed Web of Science ®Google Scholar
• CAMM AJ, KARAM R, PRATT CM: The azimilide post-infarct survival evaluation (ALIVE) trial. Am. .1. Cardiol (1998) 81 (6A):35D–39D.
   Google Scholar
• HART RG, PEARCE LA, ROTHBART PM, MCANULTY JH, ASINGER RW, HALPERIN JL: Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. Am. Coll. Cardiol (2000) 35(1):183–187.
   PubMed Web of Science ®Google Scholar
• Echocardiographic predictors of stroke inpatients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch. Intern. Med. (1998) 158(12): 1316–1320.
   PubMed Web of Science ®Google Scholar
• MANT J, FITZMAURICE D, MURRAY E, LIP GY, HOBBS FD: Long term anticoagulation or antiplatelet treatment. Inclusion criteria determine results of review. Br. Med. J. (2001) 323(7306):233–234.
   PubMedGoogle Scholar